Leriglitazone demonstrated efficacy on myelopathy, with improvements in gait control among treated patients. Most notably, progression of brain lesions was significantly more prevalent in the placebo group, suggesting a preventive effect of leriglitazone on the development of the cerebral form of the disease.
Adrenoleukodystrophy: A Promising Drug
· 11 December 2024
In this study, we tested a new treatment, leriglitazone, in 116 men with adrenomyeloneuropathy as part of a randomized, placebo-controlled trial.
